|
US8409861B2
(en)
*
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
US9745548B2
(en)
|
2012-03-15 |
2017-08-29 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US9752113B2
(en)
|
2012-03-15 |
2017-09-05 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US10967298B2
(en)
|
2012-03-15 |
2021-04-06 |
Flodesign Sonics, Inc. |
Driver and control for variable impedence load
|
|
US10322949B2
(en)
|
2012-03-15 |
2019-06-18 |
Flodesign Sonics, Inc. |
Transducer and reflector configurations for an acoustophoretic device
|
|
US9950282B2
(en)
|
2012-03-15 |
2018-04-24 |
Flodesign Sonics, Inc. |
Electronic configuration and control for acoustic standing wave generation
|
|
US10689609B2
(en)
|
2012-03-15 |
2020-06-23 |
Flodesign Sonics, Inc. |
Acoustic bioreactor processes
|
|
US9458450B2
(en)
|
2012-03-15 |
2016-10-04 |
Flodesign Sonics, Inc. |
Acoustophoretic separation technology using multi-dimensional standing waves
|
|
US10737953B2
(en)
|
2012-04-20 |
2020-08-11 |
Flodesign Sonics, Inc. |
Acoustophoretic method for use in bioreactors
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
US9745569B2
(en)
|
2013-09-13 |
2017-08-29 |
Flodesign Sonics, Inc. |
System for generating high concentration factors for low cell density suspensions
|
|
CN111218447B
(zh)
|
2013-11-07 |
2024-10-11 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
US20150166984A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting alpha-antitrypsin point mutations
|
|
CN105939767B
(zh)
|
2014-01-08 |
2018-04-06 |
弗洛设计声能学公司 |
具有双声电泳腔的声电泳装置
|
|
RU2752933C2
(ru)
|
2014-03-11 |
2021-08-11 |
Селлектис |
Способ создания т-клеток, пригодных для аллогенной трансплантации
|
|
SG11201608701QA
(en)
*
|
2014-04-18 |
2016-11-29 |
Editas Medicine Inc |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
JP2017524348A
(ja)
*
|
2014-06-10 |
2017-08-31 |
モナッシュ ユニバーシティ |
養子細胞移入のためのｐｔｐｎ２阻害を用いた白血球の産生方法
|
|
US9744483B2
(en)
|
2014-07-02 |
2017-08-29 |
Flodesign Sonics, Inc. |
Large scale acoustic separation device
|
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
KR102546296B1
(ko)
*
|
2014-10-31 |
2023-06-21 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
|
|
CN107208055B
(zh)
*
|
2015-01-17 |
2021-06-15 |
浙江大学 |
引起免疫原性反应降低的被修饰细胞
|
|
EP3250602A1
(en)
|
2015-01-26 |
2017-12-06 |
Cellectis |
T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
|
|
BR112017020750A2
(en)
*
|
2015-03-27 |
2018-06-26 |
President And Fellows Of Harvard College |
modified t-cells and methods of producing and using them
|
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
|
US11021699B2
(en)
|
2015-04-29 |
2021-06-01 |
FioDesign Sonics, Inc. |
Separation using angled acoustic waves
|
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
|
JP7033453B2
(ja)
*
|
2015-06-30 |
2022-03-10 |
セレクティス |
特異的エンドヌクレアーゼを使用した遺伝子不活化によってｎｋ細胞の機能性を改善する方法
|
|
US11474085B2
(en)
|
2015-07-28 |
2022-10-18 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
|
US11459540B2
(en)
|
2015-07-28 |
2022-10-04 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
|
EP4339287A3
(en)
|
2015-07-31 |
2024-05-22 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
|
CA2994746A1
(en)
*
|
2015-08-11 |
2017-02-16 |
Cellectis |
Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
|
|
US11091780B2
(en)
|
2015-09-18 |
2021-08-17 |
The Regents Of The University Of California |
Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof
|
|
ES2803728T3
(es)
|
2015-10-05 |
2021-01-29 |
Prec Biosciences Inc |
Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
|
|
ES2768984T3
(es)
|
2015-10-05 |
2020-06-24 |
Prec Biosciences Inc |
Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas
|
|
WO2017059557A1
(en)
*
|
2015-10-09 |
2017-04-13 |
Peking University |
Methods for enhancing in vivo persistence and efficacy of exogenously administered t cells, genetically modified t cells and method and method of use
|
|
WO2017070632A2
(en)
|
2015-10-23 |
2017-04-27 |
President And Fellows Of Harvard College |
Nucleobase editors and uses thereof
|
|
US12642852B1
(en)
*
|
2015-11-04 |
2026-06-02 |
Fate Therapeutics, Inc. |
Genomic engineering of pluripotent cells
|
|
WO2017093969A1
(en)
*
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
US11352631B2
(en)
|
2015-12-18 |
2022-06-07 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
|
AU2016374253B2
(en)
*
|
2015-12-18 |
2021-10-21 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the MHC cell receptor
|
|
US20190017075A1
(en)
*
|
2015-12-23 |
2019-01-17 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
|
|
MX2018010484A
(es)
*
|
2016-03-04 |
2019-01-10 |
Editas Medicine Inc |
Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer.
|
|
US10894093B2
(en)
|
2016-04-15 |
2021-01-19 |
Cellectis |
Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
|
|
WO2017178586A1
(en)
|
2016-04-15 |
2017-10-19 |
Cellectis |
A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
|
|
CN109414512A
(zh)
|
2016-04-22 |
2019-03-01 |
科济生物医药（上海）有限公司 |
用于细胞免疫疗法的组合物和方法
|
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
|
US11085035B2
(en)
|
2016-05-03 |
2021-08-10 |
Flodesign Sonics, Inc. |
Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
|
|
CA2937157A1
(en)
|
2016-07-25 |
2018-01-25 |
Ucl Business Ltd |
Protein-based t-cell receptor knockdown
|
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
|
KR20190062505A
(ko)
|
2016-10-03 |
2019-06-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Hpv-특이적 결합 분자
|
|
KR20240007715A
(ko)
|
2016-10-14 |
2024-01-16 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
|
EP4338799A3
(en)
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
WO2018073393A2
(en)
*
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
IL265953B2
(en)
*
|
2016-10-19 |
2026-05-01 |
Cellectis Sa |
Gene insertion designed to target for enhanced immune cell therapy
|
|
EP3529347A1
(en)
|
2016-10-19 |
2019-08-28 |
Flodesign Sonics, Inc. |
Affinity cell extraction by acoustics
|
|
JP7236380B2
(ja)
*
|
2016-10-19 |
2023-03-09 |
セレクティス |
治療に適したｔａｌエフェクターヌクレアーゼ（ｔａｌｅｎ）改変同種異系細胞
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
AU2018208614A1
(en)
*
|
2017-01-10 |
2019-07-11 |
The General Hospital Corporation |
Modified T cells and methods of their use
|
|
CN107058230B
(zh)
*
|
2017-01-20 |
2020-03-24 |
山东兴瑞生物科技有限公司 |
一种沉默t细胞抗原受体的t淋巴细胞的制备方法
|
|
KR20190123328A
(ko)
|
2017-03-09 |
2019-10-31 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
암 백신
|
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
CN110914310A
(zh)
|
2017-03-10 |
2020-03-24 |
哈佛大学的校长及成员们 |
胞嘧啶至鸟嘌呤碱基编辑器
|
|
KR20190130608A
(ko)
|
2017-03-22 |
2019-11-22 |
노파르티스 아게 |
면역종양학을 위한 조성물 및 방법
|
|
IL306092A
(en)
|
2017-03-23 |
2023-11-01 |
Harvard College |
Nucleic base editors that include nucleic acid programmable DNA binding proteins
|
|
CN110869046B
(zh)
|
2017-03-31 |
2025-02-25 |
塞勒克提斯公司 |
通用型抗cd22嵌合抗原受体工程化的免疫细胞
|
|
US10934336B2
(en)
|
2017-04-13 |
2021-03-02 |
The Trustees Of The University Of Pennsylvania |
Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy
|
|
JP7170666B2
(ja)
*
|
2017-05-08 |
2022-11-14 |
プレシジョン バイオサイエンシズ，インク． |
操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法
|
|
BR112019023608A2
(pt)
|
2017-05-12 |
2020-05-26 |
Crispr Therapeutics Ag |
Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
EP3631468A1
(en)
|
2017-06-02 |
2020-04-08 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
|
EP3638775A1
(en)
*
|
2017-06-13 |
2020-04-22 |
Fate Therapeutics, Inc. |
Compositions and methods for inducing myeloid suppressive cells and use thereof
|
|
SG11201911729SA
(en)
*
|
2017-06-16 |
2020-01-30 |
Sangamo Therapeutics Inc |
Targeted disruption of t cell and/or hla receptors
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
US20190004063A1
(en)
*
|
2017-06-30 |
2019-01-03 |
Indiana University Research & Technology Corporation |
Compositions and methods for detecting sla reactivity
|
|
EP4775669A2
(en)
|
2017-06-30 |
2026-07-15 |
Precision Biosciences, Inc. |
Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
|
|
CN111511375A
(zh)
|
2017-06-30 |
2020-08-07 |
因提玛生物科学公司 |
用于基因治疗的腺相关病毒载体
|
|
AU2018292181B2
(en)
|
2017-06-30 |
2025-04-10 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
|
EP3640333A4
(en)
*
|
2017-07-14 |
2020-12-30 |
Cure Genetics Co., Ltd |
GENE EDITING SYSTEM AND GENE EDITING METHOD
|
|
EP3658573A1
(en)
|
2017-07-28 |
2020-06-03 |
President and Fellows of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
WO2019047932A1
(zh)
*
|
2017-09-08 |
2019-03-14 |
科济生物医药（上海）有限公司 |
基因工程化的t细胞及应用
|
|
US11952408B2
(en)
|
2017-10-03 |
2024-04-09 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
|
JP2021502056A
(ja)
*
|
2017-10-05 |
2021-01-28 |
ナントセル，インコーポレイテッド |
脂質ベースの抗原及びｎｋ細胞上のｔ細胞受容体
|
|
CA3082251A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
|
JP7621795B2
(ja)
*
|
2017-10-19 |
2025-01-27 |
セレクティス |
改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み
|
|
CN107723275B
(zh)
*
|
2017-10-20 |
2020-09-04 |
重庆精准生物技术有限公司 |
通用型car-t细胞及其制备方法和应用
|
|
CN109694854B
(zh)
*
|
2017-10-20 |
2023-11-21 |
亘喜生物科技（上海）有限公司 |
通用型嵌合抗原受体t细胞制备技术
|
|
CN109750035B
(zh)
*
|
2017-11-02 |
2020-06-05 |
上海邦耀生物科技有限公司 |
靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA
|
|
TW201923073A
(zh)
*
|
2017-11-20 |
2019-06-16 |
新加坡商泰莎治療私人有限公司 |
經修飾之k562細胞
|
|
WO2019110693A1
(en)
|
2017-12-05 |
2019-06-13 |
Celyad S.A. |
Compositions and methods for improving persistence of cells for adoptive transfer
|
|
CA3082204A1
(en)
*
|
2017-12-13 |
2019-06-20 |
Janssen Biotech, Inc. |
Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
|
|
CN114900773A
(zh)
|
2017-12-14 |
2022-08-12 |
弗洛设计声能学公司 |
声泳系统及其操作方法、控制声换能器及声学系统的方法
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
US11227325B1
(en)
|
2017-12-18 |
2022-01-18 |
Wells Fargo Bank, N.A. |
Event-based automatic transaction system
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
TW201934575A
(zh)
*
|
2018-02-11 |
2019-09-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種分離的嵌合抗原受體以及包含其的修飾ｔ細胞及用途
|
|
EP3754018A4
(en)
*
|
2018-02-16 |
2021-11-24 |
Kyoto University |
METHOD OF MANUFACTURING A WEAK ANTIGENT CELL
|
|
CA3090793C
(en)
*
|
2018-02-16 |
2024-10-08 |
Kite Pharma, Inc. |
MODIFIED MULTIPOTENTED STEM CELLS, AND METHODS OF PREPARATION AND USE
|
|
CN112585276A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
产生表达重组受体的细胞的方法和相关组合物
|
|
CN112566698A
(zh)
|
2018-04-05 |
2021-03-26 |
朱诺治疗学股份有限公司 |
T细胞受体和表达该t细胞受体的工程化细胞
|
|
CN112585277A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
表达重组受体的t细胞、相关多核苷酸和方法
|
|
KR102617818B1
(ko)
|
2018-04-12 |
2023-12-27 |
프리시젼 바이오사이언시스 인코포레이티드 |
인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제
|
|
WO2019204664A2
(en)
*
|
2018-04-19 |
2019-10-24 |
Apdn (B.V.I), Inc. |
Engineered lymphocyte compositions, methods and systems
|
|
CN112189018A
(zh)
|
2018-04-20 |
2021-01-05 |
汉诺威医学院 |
结合疱疹病毒抗原的嵌合抗原受体和car-t细胞
|
|
WO2019210281A1
(en)
*
|
2018-04-27 |
2019-10-31 |
Casebia Therapeutics Limited Liability Partnership |
Methods and compositions of cytotoxic t cell depletion
|
|
WO2019210131A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US20200063100A1
(en)
|
2018-05-11 |
2020-02-27 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer
|
|
WO2019226953A1
(en)
|
2018-05-23 |
2019-11-28 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
EP3820495A4
(en)
|
2018-07-09 |
2022-07-20 |
The Broad Institute Inc. |
RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
|
|
US12378572B2
(en)
|
2018-09-07 |
2025-08-05 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
AU2019341365A1
(en)
*
|
2018-09-21 |
2021-05-27 |
Crage Medical Co., Limited |
Method for gene editing of cell on the basis of CRISPR/Cas system
|
|
CA3116132A1
(en)
|
2018-10-16 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
CN109266618B
(zh)
*
|
2018-10-18 |
2021-04-23 |
赛元生物科技(杭州)有限公司 |
能够靶向肿瘤细胞的巨噬细胞及其制备方法
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
EA202191257A1
(ru)
*
|
2018-11-07 |
2021-12-06 |
Криспр Терапьютикс Аг |
Противораковая терапия на основе иммуноцитов, связывающих liv1
|
|
SG11202103832SA
(en)
*
|
2018-11-07 |
2021-05-28 |
Crispr Therapeutics Ag |
Anti-cd33 immune cell cancer therapy
|
|
CN113226340A
(zh)
|
2018-11-26 |
2021-08-06 |
恩卡尔塔公司 |
同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
|
|
CN111349606A
(zh)
*
|
2018-12-20 |
2020-06-30 |
上海恒润达生生物科技有限公司 |
P60抑制剂与cart细胞联合应用
|
|
US12583896B2
(en)
|
2019-01-07 |
2026-03-24 |
The Regents Of The University Of California |
Caged-degron-based molecular feedback circuits and methods of using the same
|
|
EP3908665A4
(en)
*
|
2019-01-07 |
2022-10-12 |
The Regents of the University of California |
SYNTHETIC MOLECULAR FEEDBACK CIRCUITS AND METHODS OF USE
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
CN109706121A
(zh)
*
|
2019-01-25 |
2019-05-03 |
苏州茂行生物科技有限公司 |
一种基于碱基编辑的通用型car-t细胞及其制备方法和应用
|
|
US12600971B2
(en)
|
2019-02-13 |
2026-04-14 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
AU2020226893B2
(en)
*
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
JP7579795B2
(ja)
|
2019-02-21 |
2024-11-08 |
マレンゴ・セラピューティクス，インコーポレーテッド |
ＮＫｐ３０に結合する抗体分子およびその使用
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
WO2020191241A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
|
EP4332115A3
(en)
|
2019-04-03 |
2024-05-29 |
Precision Biosciences, Inc. |
Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
CN111826352A
(zh)
*
|
2019-04-22 |
2020-10-27 |
苏州方德门达新药开发有限公司 |
通用型car-t细胞、其制备及应用
|
|
CA3138633A1
(en)
|
2019-04-30 |
2020-11-05 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
CN114174325A
(zh)
*
|
2019-06-04 |
2022-03-11 |
恩卡尔塔公司 |
用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合
|
|
TW202115245A
(zh)
*
|
2019-06-27 |
2021-04-16 |
丹麥商諾佛 儂迪克股份有限公司 |
安全免疫隱形細胞
|
|
CA3144549A1
(en)
*
|
2019-06-28 |
2020-12-30 |
Cafa Therapeutics Limited |
Cell for resisting transplant reaction and method
|
|
JP7657742B2
(ja)
*
|
2019-08-29 |
2025-04-07 |
▲かい▼興生命科技（上海）有限公司 |
移植拒絶反応に抵抗する細胞及び方法
|
|
US11116798B2
(en)
*
|
2019-09-05 |
2021-09-14 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
US11104918B2
(en)
*
|
2019-09-05 |
2021-08-31 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
US12594301B2
(en)
|
2019-09-27 |
2026-04-07 |
Beam Therapeutics Inc. |
Compositions and methods for treatment of liquid cancers
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
EP4048295A1
(en)
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
IL292740A
(en)
*
|
2019-11-05 |
2022-07-01 |
Lonza Walkersville Inc |
Allogeneic t cells and methods for their production
|
|
AU2020382219A1
(en)
|
2019-11-13 |
2022-05-12 |
Crispr Therapeutics Ag |
Manufacturing process for making T cells expressing chimeric antigen receptors
|
|
BR112022009181A2
(pt)
*
|
2019-11-25 |
2022-07-26 |
Univ Kyoto |
Sistema para prover um produto de célula t, métodos para produzir um produto de célula t, para construir um banco celular e uma coleção de produto de célula t e para prover um produto de célula t, banco celular, coleções de banco celular e de produto de célula t, e, produto de célula t
|
|
EP4081537A1
(en)
|
2019-12-23 |
2022-11-02 |
Cellectis |
New mesothelin specific chimeric antigen receptors (car) for solid tumors cancer immunotherapy
|
|
WO2021138474A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
JP2023511965A
(ja)
*
|
2020-01-23 |
2023-03-23 |
カンステム バイオテック カンパニー リミテッド |
Ｏｆｆ－ｔｈｅ－ｓｈｅｌｆ幹細胞および免疫細胞、それを含む薬学的組成物
|
|
WO2021202581A1
(en)
*
|
2020-03-30 |
2021-10-07 |
WUGEN, Inc. |
Engineered immune cells for adoptive cell therapy
|
|
JP7821119B2
(ja)
*
|
2020-04-23 |
2026-02-26 |
エーゼットセラピーズ， インコーポレイテッド |
Ｈｌａクラスｉ ｍｈｃの細胞切除
|
|
CA3177481A1
(en)
|
2020-05-08 |
2021-11-11 |
David R. Liu |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
MX2022015586A
(es)
|
2020-06-12 |
2023-03-15 |
Nkarta Inc |
Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.
|
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
EP4176261A1
(en)
|
2020-07-03 |
2023-05-10 |
Cellectis S.A. |
Method for determining potency of chimeric antigen receptor expressing immune cells
|
|
WO2022007784A1
(en)
*
|
2020-07-06 |
2022-01-13 |
Nanjing Legend Biotech Co., Ltd. |
Methods of reducing graft rejection of allogeneic cell therapy
|
|
KR102932097B1
(ko)
*
|
2020-07-06 |
2026-02-27 |
주식회사 지씨셀 |
면역원성이 감소된 신규한 이식용 세포
|
|
WO2022018262A1
(en)
|
2020-07-24 |
2022-01-27 |
Cellectis S.A. |
T-cells expressing immune cell engagers in allogenic settings
|
|
BR112023001292A2
(pt)
|
2020-07-31 |
2023-02-14 |
Cellectis Sa |
Células t duplo-car
|
|
EP4058474B1
(en)
*
|
2020-08-20 |
2024-05-08 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating egfr positive cancers
|
|
AU2021347359A1
(en)
|
2020-09-25 |
2023-05-18 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
CN114426583B
(zh)
*
|
2020-10-29 |
2023-10-10 |
中国科学技术大学 |
用于急性髓系白血病的细胞疗法的嵌合抗原受体
|
|
CN114525259B
(zh)
*
|
2020-11-03 |
2025-02-14 |
南京北恒生物科技有限公司 |
靶向cd7的嵌合抗原受体及其用途
|
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
IL303269A
(en)
|
2020-12-03 |
2023-07-01 |
Century Therapeutics Inc |
Genetically engineered cells and uses thereof
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
EP4255453A4
(en)
*
|
2020-12-03 |
2025-03-26 |
Nkarta, Inc. |
Methods for manipulating immune cells for increased potency and persistence, as well as uses of engineered cells in immunotherapy
|
|
TW202241935A
(zh)
|
2020-12-18 |
2022-11-01 |
美商世紀治療股份有限公司 |
具有可調適受體專一性之嵌合抗原受體系統
|
|
CN114657137A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向BTLA的shRNA和/或shRNA-miR的多能干细胞或其衍生物
|
|
EP4271798A1
(en)
|
2020-12-30 |
2023-11-08 |
CRISPR Therapeutics AG |
Compositions and methods for differentiating stem cells into nk cells
|
|
US11566230B2
(en)
|
2020-12-31 |
2023-01-31 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
CA3206549A1
(en)
|
2021-01-29 |
2022-08-04 |
Frederick G. Vogt |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
WO2022171179A1
(zh)
|
2021-02-10 |
2022-08-18 |
苏州克睿基因生物科技有限公司 |
一种扩增增强子及其应用
|
|
KR20230165771A
(ko)
|
2021-03-03 |
2023-12-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법 및 dgk 억제제의 조합
|
|
TW202304480A
(zh)
|
2021-03-19 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
腫瘤浸潤淋巴球（ｔｉｌ）中之與ｃｄ３９／ｃｄ６９選擇及基因剔除相關之ｔｉｌ擴增之方法
|
|
CN118019546A
(zh)
|
2021-03-23 |
2024-05-10 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞的cish基因编辑及其在免疫疗法中的用途
|
|
WO2022229412A1
(en)
|
2021-04-30 |
2022-11-03 |
Cellectis S.A. |
New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy
|
|
US20240269180A1
(en)
|
2021-05-17 |
2024-08-15 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
EP4341300A1
(en)
|
2021-05-21 |
2024-03-27 |
Cellectis S.A. |
Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
|
|
CA3219830A1
(en)
*
|
2021-05-24 |
2022-12-01 |
Lei Zhang |
Ciita targeting zinc finger nucleases
|
|
CA3226111A1
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
|
CN117858943A
(zh)
*
|
2021-08-24 |
2024-04-09 |
赛斯尔擎生物技术（上海）有限公司 |
T细胞产品及其用途
|
|
CA3231670A1
(en)
*
|
2021-09-10 |
2023-03-16 |
Kite Pharma, Inc. |
Alternative generation of allogeneic human t cells
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
CA3249825A1
(en)
*
|
2022-01-25 |
2023-08-03 |
Brl Medicine (Shanghai) Co., Ltd. |
MODIFIED CELLS AND THEIR USES
|
|
EP4469065A1
(en)
|
2022-01-28 |
2024-12-04 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
WO2023151620A1
(zh)
*
|
2022-02-09 |
2023-08-17 |
恺兴生命科技(上海)有限公司 |
用于细胞免疫学的组合物和方法
|
|
EP4504221A4
(en)
*
|
2022-03-22 |
2026-02-25 |
Celyntra Therapeutics Sa |
Compositions and methods for generating cells with reduced immunogenicity
|
|
JP2025512313A
(ja)
|
2022-04-06 |
2025-04-17 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
WO2023201340A2
(en)
*
|
2022-04-15 |
2023-10-19 |
The General Hospital Corporation |
Compositions and methods for reducing cell therapy immunogenicity
|
|
CN117004604A
(zh)
*
|
2022-04-28 |
2023-11-07 |
南京北恒生物科技有限公司 |
一种ciita基因被敲除的工程化免疫细胞及其用途
|
|
EP4522202A1
(en)
|
2022-05-10 |
2025-03-19 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
|
EP4282963A1
(en)
|
2022-05-23 |
2023-11-29 |
Eberhard Karls Universität Tübingen, Medizinische Fakultät |
Nucleic acid modified biological cell with expansion-dependent gene expression
|
|
CN114958768B
(zh)
*
|
2022-06-02 |
2023-03-24 |
健颐生物科技发展(山东)有限公司 |
Fgf10旁分泌通用型人成纤维细胞制剂的制备方法
|
|
EP4547826A1
(en)
|
2022-06-30 |
2025-05-07 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
|
CN117384852B
(zh)
*
|
2022-07-11 |
2026-01-16 |
士泽生物医药（苏州）有限公司 |
一种表达lgals9的通用型细胞及其制备方法
|
|
KR20250061756A
(ko)
|
2022-09-08 |
2025-05-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
|
|
EP4611823A1
(en)
|
2022-11-03 |
2025-09-10 |
Cellectis S.A. |
Enhancing efficacy and safety of t-cell-mediated immunotherapy
|
|
EP4612277A1
(en)
|
2022-11-04 |
2025-09-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
WO2024121385A1
(en)
|
2022-12-09 |
2024-06-13 |
Cellectis S.A. |
Two-dose regimen in immunotherapy
|
|
US20260232729A1
(en)
|
2023-02-03 |
2026-08-13 |
C3S2 Gmbh |
Methods for non-viral manufacturing of engineered immune cells
|
|
WO2025054540A1
(en)
|
2023-09-08 |
2025-03-13 |
Iovance Biotherapeutics, Inc. |
Methods of gene-editing using programmable nucleases
|
|
CN119351338B
(zh)
*
|
2023-09-15 |
2026-01-23 |
士泽生物医药（苏州）有限公司 |
一种表达cd300ld的低免疫原性细胞及其制备方法
|
|
US20250345431A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|
|
WO2026002165A1
(zh)
*
|
2024-06-26 |
2026-01-02 |
香港北恒生物科技有限公司 |
工程化免疫细胞及其用途
|
|
WO2026025092A1
(en)
|
2024-07-26 |
2026-01-29 |
Juno Therapeutics, Inc. |
Synthetic promoters for t cell expression
|